(2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Tetrahydropyran-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide

The systematic IUPAC designation (2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide corresponds to the lincosamide antibiotic base universally recognized by the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) as clindamycin. The substance is a 7-deoxy-7-chloro semisynthetic congener of lincomycin, wherein stereospecific substitution of the C-7 hydroxyl with chlorine yields a 2.0- to 4.0-fold enhancement in ribosomal binding affinity to the 50S subunit of susceptible organisms. Bulk material is typically supplied as the hydrochloride monohydrate salt (CAS 21462-39-5) or the phosphate ester prodrug, though the free base form described here serves as the pivotal intermediate for salt formation and is routinely characterized during active pharmaceutical ingredient (API) release by HPLC assay per USP monograph 0.37% w/w acceptance criteria for total impurities.

Stereochemical Purity and Pharmacopeial Compliance Boundaries

Control of the four chiral centres specified in the IUPAC string—(2S,4R) in the pyrrolidine ring and (2R,3R,4S,5R,6R) in the methylsulfanyl-tetrahydropyran moiety—is enforced through pharmacopeial specific rotation limits of +135° to +150° (c=1, water, calculated on the anhydrous basis for the hydrochloride salt) and by chiral HPLC impurity profiling. The 6R-methylsulfanyl configuration is particularly sensitive to epimerization under alkaline process conditions; a drift of 0.5 log units in pH during the final crystallization of the hydrochloride can generate the 6S-epimer at levels exceeding 0.15%, triggering batch rejection under the Ph. Eur. monograph 0165 unspecified impurity threshold of 0.10%. Production-scale campaigns at 500–2000 L glass-lined reactors with retreat-curve impellers routinely observe a diastereomeric ratio (DR) envelope of >99.8:0.2 when the quench temperature after chlorination is kept within −5 °C to 0 °C. Deviation to +5 °C has been shown to collapse the DR to 98.5:1.5 across multiple contract manufacturing organization (CMO) batch records, with the unnatural epimer co-eluting at relative retention time 1.18 on a C18 column under the isocratic methanol-phosphate buffer system prescribed in USP <1382> (clindamycin phosphate assay). Routine pharmacopeial testing also mandates residual solvent limits per USP <467> method IV, with headspace GC-MS quantification of methylene chloride—the primary chlorination solvent—held below 600 ppm for oral-grade API and below 300 ppm for injectable grades compliant with ICH Q3C Option 2 limits.

How Does the 7-Chloro Substituent Alter Ribosomal Binding Kinetics?

Comparative X-ray crystallographic data of the clindamycin-50S complex (PDB 1YHQ) reveal that the 7-chloro substituent forms a Van der Waals contact with the 2’-hydroxyl of A2058 in the peptidyl transferase centre, a spatial gap inaccessible to the parent lincomycin hydroxyl. This translates into an in vitro protein synthesis inhibition IC₅₀ of 0.15 μg/mL for clindamycin base against Staphylococcus aureus ATCC 25923, versus 0.6 μg/mL for lincomycin, as measured by a [³⁵S]methionine incorporation assay in early-log-phase cultures. The consequence in minimum inhibitory concentration (MIC) distributions is a modal shift of 2 dilution steps when comparing CLSI M100 broth microdilution panels for methicillin-susceptible S. aureus, with clindamycin delivering an MIC₅₀ of 0.12 mg/L compared to 0.5 mg/L for lincomycin. Clinically, the lone structural alteration—O → Cl—also abrogates the inducible erm-mediated methylation of A2058 to a degree, though constitutive methylase expression still confers high-level resistance. This nuance is captured in the routine D-test procedure (CLSI M100 Table 2E) where a blunted zone of inhibition between erythromycin and clindamycin signifies inducible macrolide-lincosamide-streptogramin B resistance, rendering the isolate clindamycin-resistant despite an apparently susceptible MIC. Distinguishing the product from oxazolidinones such as linezolid, which bind the 23S rRNA at a distinct overlapping site near the P-site, clindamycin does not exhibit bacteriostatic activity against Enterococcus faecium with an MIC₉₀ of >64 mg/L, a difference exploited in antimicrobial stewardship protocols for vancomycin-resistant enterococcal (VRE) infections where linezolid is preferred.

Process Control in the Chlorination Cascade

No section header precedes this paragraph. The conversion of lincomycin hydrochloride to clindamycin hydrochloride proceeds via a Vilsmeier-type intermediate formed from thionyl chloride and dimethylformamide in methylene chloride, with retention of configuration at C-7 mediated through a bicyclic oxazaphospholidine transition state when a phosphine oxide activator—typically triphenylphosphine oxide—is utilised in a molar ratio of 1.05 equivalents relative to lincomycin. Industrial batch data from a 1600 L Hastelloy C-22 loop reactor with external heat-exchange surface area of 12 m² indicate that the heat of reaction (−210 kJ/mol lincomycin) must be dissipated within 15 seconds of thionyl chloride dosing to prevent a runaway exotherm that generates 3.8–4.2% of the 7,7-dichloro by-product. The adoption of continuous flow chlorination in Corning Advanced-Flow reactors (G1 SiC plates, 10 mL internal volume) has been documented to reduce this by-product to 0.15% at a residence time of 45 seconds and a process temperature of −2 °C, achieving a titre of 92% conversion with a throughput of 1.2 kg/h. Post-chlorination, the reaction mass is quenched into 25% w/w aqueous sodium carbonate at 0–5 °C under high-shear mixing; slower polish filtration through 0.2 μm PTFE membranes prior to pH adjustment eliminates colloidal phosphorus-containing precipitates that otherwise act as nucleation sites for amorphous clindamycin base precipitation, leading to filtration times exceeding 45 minutes on an 8-m² plate-and-frame filter press. The resulting crystalline clindamycin free base exhibits a characteristic XRPD pattern with prominent peaks at 2θ = 8.3°, 16.7°, and 22.1° (Cu Kα), and differential scanning calorimetry thermograms show a single endothermic melt at 143.8 °C (ΔH_fus = 48.6 J/g).

Physical-Chemical Specifications for Different Dosage Form Routes

Beyond compendial identity and purity metrics, the particle size distribution (PSD) of micronized clindamycin hydrochloride is a de facto critical quality attribute for solid oral and topical formulations. Laser diffraction data (Malvern Mastersizer 3000, wet dispersion in isopropyl alcohol with 0.1% lecithin surfactant) show that D₉₀ ≤ 20 µm is required for adequate flowability and content uniformity in direct compression blends lubricated with 0.5% sodium stearyl fumarate; higher D₉₀ values of 40–50 µm are acceptable for roller-compacted granules destined for capsule filling on a Bosch GKF 3000 encapsulator with dosing disc speeds up to 100,000 capsules/hour. For topical gel systems containing clindamycin phosphate, the pH specification of the aqueous-phase gel concentrate is held at 5.5–6.0 to balance phosphate ester hydrolysis kinetics (activation energy E_a = 72 kJ/mol, determined by accelerated stability at 40 °C/75% RH) against dermal irritation potential. The base trace in the phosphate API must not exceed 0.5% w/w, as the free base partition coefficient (log P 2.16) facilitates sebaceous follicle penetration but also introduces a bitter taste threshold below 10 ppm that can compromise palatability in liquid pediatric formulations if present above 50 ppm in the reconstituted syrup.

When Polymeric Incompatibility Limits Aqueous-Phase Stability

Clindamycin phosphate, the water-soluble prodrug preferred in parenteral and topical products, undergoes hydrolysis to the active base via endogenous phosphatases in vivo, but its aqueous stability is profoundly affected by the ionisation state of excipients. Formulation at pH 6.3 in a 5% w/w polysorbate 80-containing vehicle has been observed to reduce phosphate ester hydrolysis half-life (t_1/2) from 180 days to 42 days at 25 °C when 10% w/w zinc oxide is co-formulated, owing to divalent cation-catalysed phosphoester cleavage. Consequently, monographs for clindamycin-benzoyl peroxide combination products (e.g., BenzaClin® gel) require separate packaging of the clindamycin phosphate component and the oxidising agent, with in situ mixing at the point of dispensing. In intravenous admixtures, incompatibility arises with aminophylline and ampicillin sodium at concentrations exceeding 6 mg/mL, manifesting as visible particulate formation within 24 hours when the admixture is stored under ambient fluorescent light, per data filed in FDA NDA 050601 (clindamycin phosphate injection). This photo-instability of the 7-chloro substituent in dilute aqueous solution—producing dechlorinated lincomycin and a characteristic yellow chromophore (λ_max 420 nm)—necessitates protective overwrapping of infusion bags during administration, a requirement not applicable to the more photostable lincomycin hydrochloride solution, which lacks the 7-chlorine.

Therapeutic Spectrum Gaps Differentiating Clindamycin from Macrolides and Oxazolidinones

Anaerobic coverage is the principal clinical differentiator. Direct comparison of EUCAST MIC distributions for Bacteroides fragilis group isolates shows clindamycin with an MIC_50/90 of 0.5/8 mg/L, whereas erythromycin is inactive (MIC₉₀ >32 mg/L) and linezolid demonstrates an MIC₉₀ of 4 mg/L but lacks regulatory labelling for intra-abdominal sepsis. This is attributed to the unique interaction of the methylsulfanyl-tetrahydropyran sugar moiety with the 23S rRNA domain V, a contact not fully reproduced by the acetamide-type side chain of linezolid. In surgical prophylaxis, a single intravenous dose of 900 mg clindamycin phosphate (equivalent to 600 mg clindamycin base) given 30 minutes before incision achieves gingival crevicular fluid concentrations above 4 mg/L—exceeding the MIC₉₀ for oral anaerobes—for a duration of 6 hours, validated by microdialysis studies that report a tissue-to-plasma AUC ratio of 0.72 ± 0.11. In contrast, azithromycin reaches crevicular fluid concentrations of only 0.8 mg/L at 2.5 hours post-dose, insufficient to cover Prevotella melaninogenica strains with MIC values of 1–2 mg/L.

The deployment of clindamycin for staphylococcal toxigenic syndromes (e.g., necrotising fasciitis, toxic shock) leverages its ability to suppress exotoxin production at sub-inhibitory concentrations (0.25× MIC), a property quantified by an in vitro α-toxin suppression assay that records 80% reduction in haemolytic activity at 0.03 mg/L clindamycin against S. aureus strain MW2, whereas vancomycin at 2 mg/L enhances toxin release through cell wall stress-mediated agr activation. This mechanistic nuance is absent in β-lactam comparators, which at supra-MIC concentrations trigger massive toxin liberation. However, the clinical utility is constrained by the prevalence of inducible clindamycin resistance in MRSA isolates; surveillance data from the SENTRY Antimicrobial Surveillance Program (2019–2023) record 14.2% inducible resistance among S. aureus bloodstream isolates in North America, rising to 33.7% in Asia-Pacific regions where erm gene carriage exceeds 60%. In such epidemiological settings, the product must be restricted to confirmed D-test-negative isolates, a limitation communicated explicitly in the CLSI M100 footnote for clindamycin susceptibility reporting.

As a semi-synthetic lincosamide, the product bridges the antimicrobial gap between narrow-spectrum lincomycin (restricted largely to Gram-positive aerobes) and the broad-spectrum macrolides that lack robust anti-anaerobic activity. The presence of the 7-chloro substituent, the 6R-methylsulfanyl group stereochemistry, and the N-methyl-4-propyl-pyrrolidine-2-carboxamide scaffold collectively define a pharmacophore that has guided subsequent structure-activity relationship studies for 23S rRNA-targeted antibacterials, though no subsequent clinical candidate has supplanted this scaffold for anti-anaerobic indications since its initial FDA approval in 1970 (NDA 050105).